文献速递慢性肾脏病急性肾损伤

系统性炎症与CKD患者ESKD、主要心血管事件及死亡的相关性

ESKD, Major Cardiovascular Events, and Death Associated With Systemic Inflammation.
PubMed 文献 · Kidney Int Rep · 2026-02-17

本研究基于TRINETX平台比较hsCRP≥2 mg/l与<2 mg/l的CKD患者,倾向评分匹配后各27,580例。结果显示hsCRP≥2 mg/l与主要心血管事件和死亡风险升高相关,但与ESKD风险无关;在糖尿病患者中hsCRP≥2 mg/l与ESKD风险升高相关。

要点

  • CKD 3-4期或A3患者中,hsCRP≥2 mg/l与MACE和死亡风险升高独立相关。
  • 总体CKD人群中hsCRP≥2 mg/l与ESKD风险无显著关联。
  • 糖尿病患者中hsCRP≥2 mg/l与ESKD风险升高相关。

核心结论

  • 系统性炎症与CKD 3-4期或白蛋白尿A3患者的主要心血管事件和死亡风险升高相关,独立于传统危险因素。
  • 在糖尿病患者中,系统性炎症与ESKD风险升高相关。

研究设计与样本

  • 基于TRINETX平台的比较研究,纳入163,854例CKD患者(eGFR<60 ml/min per 1.73 m2或尿白蛋白肌酐比>200 mg/g),且有hsCRP结果且无合并感染。
  • 倾向评分匹配后,hsCRP≥2 mg/l组与hsCRP<2 mg/l组各27,580例,传统心血管危险因素匹配良好。

主要发现

  • 随访期间,hsCRP≥2 mg/l与MACE和死亡风险升高相关(HR 1.941,95%CI 1.853-2.032),与ESKD风险无关(HR 1.271,95%CI 0.893-1.809)。
  • 在21,700例糖尿病患者中,hsCRP≥2 mg/l与MACE和死亡风险升高相关,并与ESKD风险升高相关(HR 1.508,95%CI 0.997-2.281,P=0.05)。

关键数值与推荐

  • hsCRP≥2 mg/l为高炎症组定义阈值,对照组为hsCRP<2 mg/l。
  • CKD定义:eGFR<60 ml/min per 1.73 m2(KDIGO CKD 3-4期)或尿白蛋白肌酐比>200 mg/g(KDIGO A3)。

临床怎么用

  • 对CKD 3-4期或A3患者,可考虑检测hsCRP以识别心血管事件和死亡高风险人群。
  • 对合并糖尿病的CKD患者,hsCRP≥2 mg/l可能提示ESKD风险升高,需加强监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Systemic inflammation may play a role in the progression of chronic kidney disease (CKD) and in the development of major cardiovascular events (MACE). Whether this effect is independent of traditional cardiovascular risks is unclear. METHODS: In this study, we compared the incidence of end-stage kidney disease (ESKD) (i.e., chronic dialysis or renal transplantation), MACE, and death in patients with CKD with high sensitivity C-reactive protein (hsCRP) ≥ 2 mg/l versus hsCRP < 2 mg/l, using the TRINETX platform. RESULTS: Overall, 163,854 subjects with CKD (defined as estimated glomerular filtration rate [eGFR] < 60 ml/min per 1.73 m2, Kidney Disease: Improving Global Outcomes [KDIGO] CKD 3-4) or albumin-to-creatinine ratio > 200 mg/g) (KDIGO A3), hsCRP results, and no concomitant infection were included. After propensity score matching, 27,580 patients with hsCRP ≥ 2 mg/l were compared with 27,580 subjects with hsCRP < 2 mg/l, well-matched for traditional cardiovascular risk factors, including blood pressure, low-density lipoprotein (LDL) cholesterol, baseline treatments, eGFR, and albuminuria. hsCRP ≥ 2 mg/l was associated with a higher risk of MACE (ischemic stroke, myocardial infarction, heart failure, and atrial and ventricular fibrillation) and death (hazard ratio [HR]: 1.941 [95% confidence interval [CI]: 1.853-2.032]) but not a higher risk of ESKD (HR: 1.271 [0.893-1.809]) versus hsCRP < 2 mg/l during follow-up. Among patients with diabetes (21,700 patients), hsCRP ≥ 2 mg/l was associated with higher risks of MACE and death as well as with a higher risk of ESKD (HR: 1.508 [0.997-2.281], P = 0.05). CONCLUSION: Systemic inflammation is associated with a higher risk of MACE and death among subjects with CKD 3 and 4 or albuminuria (A3), and a higher risk of ESKD among patients with diabetes mellitus, independently of traditional risk factors.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Halimi JM, Maisons V, de Fréminville JB, et al. ESKD, Major Cardiovascular Events, and Death Associated With Systemic Inflammation. Kidney Int Rep. 2026. PMID: 41853745. doi:10.1016/j.ekir.2026.106364

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。